<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00716170</url>
  </required_header>
  <id_info>
    <org_study_id>1301831410</org_study_id>
    <nct_id>NCT00716170</nct_id>
  </id_info>
  <brief_title>GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia</brief_title>
  <official_title>The Role of GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Danish Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Danish Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Herlev Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In order to investigate the mechanisms underlying the hyperglucagonemia characterizing
      patients with type 2 diabetes mellitus (T2DM) we wish to test the following hypothesis: Do
      pancreatic alpha-cells exhibit inappropriate glucagon responses to substances released from
      the small intestine (GIP, GLP-2 and GLP-2) in patients with T2DM?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with T2DM are not able to suppress their secretion of glucagon after a meal or after
      oral ingestion of glucose. Patients actually respond with pathological high plasmaglucagon
      concentrations to these stimuli. Previous studies have shown that postprandial
      hyperglucagonemia results in increased hepatic glucose production and therefore contributes
      significantly to the hyperglycemia characterizing these patients.

      Recently we have shown that patients with T2DM exhibit a normal suppression of glucagon
      secretion following an adjustable intravenous (iv) glucose challenge mimicking the glucose
      excursion following a 50-g oral glucose tolerance test (OGTT) with the latter resulting in
      lack of glucagon suppression. Why this difference? A possible explanation could be that the
      oral administration stimulates intestinal factors resulting in a differentially glucagon
      response to the two similar glucose excursions. We wish to establish whether GIP, GLP-1
      and/or GLP-2 are responsible for the inappropriate glucagon suppression following OGTT and
      meals in patients with T2DM.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma glucagon responses</measure>
    <time_frame>3 hours</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">10</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>A:</arm_group_label>
    <description>Patients with type 2 diabetes mellitus</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)</intervention_name>
    <description>Day A: Oral glucose tolerance test (50g glucose)
Day B: Isoglycemic intravenous (iv) glucose infusion
Day C: Isoglycemic iv glucose infusion + iv GIP infusion (0-20 min: 4 pmol/kg body weight/min; 20-50 min: 2 pmol/kg body weight/min)
Day D: Isoglycemic iv glucose infusion + iv GLP-1 infusion (0-20 min: 0,6 pmol/kg body weight/min; 20-50 min: 0,3 pmol/kg body weight/min)
Day E: Isoglycemic iv glucose infusion + iv GLP-2 infusion (0-20 min: 1 pmol/kg body weight/min; 20-50 min: 0,5 pmol/kg body wight/min)
Day F: Isoglycemic iv glucose infusion + iv infusion of GIP, GLP-1 and GLP-2 in doses as Day C, D and E.</description>
    <arm_group_label>A:</arm_group_label>
    <other_name>Human GIP (glucose-dependent insulinotropic polypeptide)</other_name>
    <other_name>Human GLP-1 (glucagon-like peptide-1)</other_name>
    <other_name>Human GLP-2 (glucagon-like peptide-2)</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood plasma and leucocytes
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The patients will be recruted from the outpatient clinic of Department of Endocrinology,
        Herlev Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Caucasians with diet and/or tablet treated T2DM of at least 3 months duration
             (diagnosed according to the criterias of the World Health Organization (WHO))

          -  Normal Hemoglobin

          -  Prior Informed Consent

        Exclusion Criteria:

          -  Liver disease (ALAT/ASAT &gt; 2 x upper normal value)

          -  Diabetic nephropathy (se-creatinin &gt; 130 um and/or albuminuria

          -  Treatment with drugs that cannot be discontinued for 12 hours
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tina Vilsbøll, MD DMSc</last_name>
    <role>Study Chair</role>
    <affiliation>Herlev Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Filip K Knop, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>Gentofte Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Endocrinology J, Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003 Jan;26 Suppl 1:S5-20.</citation>
    <PMID>12502614</PMID>
  </reference>
  <reference>
    <citation>Unger RH, Orci L. Glucagon and the A cell: physiology and pathophysiology (first two parts). N Engl J Med. 1981 Jun 18;304(25):1518-24.</citation>
    <PMID>7015132</PMID>
  </reference>
  <reference>
    <citation>Unger RH, Orci L. Glucagon and the A cell: physiology and pathophysiology (second of two parts). N Engl J Med. 1981 Jun 25;304(26):1575-80.</citation>
    <PMID>7015135</PMID>
  </reference>
  <reference>
    <citation>Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2000 Nov;85(11):4053-9.</citation>
    <PMID>11095432</PMID>
  </reference>
  <reference>
    <citation>Knop FK, Vilsbøll T, Madsbad S, Holst JJ, Krarup T. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. Diabetologia. 2007 Apr;50(4):797-805. Epub 2007 Jan 16.</citation>
    <PMID>17225124</PMID>
  </reference>
  <reference>
    <citation>Nauck MA, Homberger E, Siegel EG, Allen RC, Eaton RP, Ebert R, Creutzfeldt W. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986 Aug;63(2):492-8.</citation>
    <PMID>3522621</PMID>
  </reference>
  <reference>
    <citation>Knop FK, Vilsbøll T, Højberg PV, Larsen S, Madsbad S, Vølund A, Holst JJ, Krarup T. Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state? Diabetes. 2007 Aug;56(8):1951-9. Epub 2007 May 18.</citation>
    <PMID>17513701</PMID>
  </reference>
  <reference>
    <citation>Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 1993 Aug;36(8):741-4.</citation>
    <PMID>8405741</PMID>
  </reference>
  <reference>
    <citation>Holst JJ. On the physiology of GIP and GLP-1. Horm Metab Res. 2004 Nov-Dec;36(11-12):747-54. Review.</citation>
    <PMID>15655703</PMID>
  </reference>
  <reference>
    <citation>Meier JJ, Gallwitz B, Siepmann N, Holst JJ, Deacon CF, Schmidt WE, Nauck MA. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia. 2003 Jun;46(6):798-801. Epub 2003 May 23.</citation>
    <PMID>12764578</PMID>
  </reference>
  <reference>
    <citation>Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993 Jan;91(1):301-7.</citation>
    <PMID>8423228</PMID>
  </reference>
  <reference>
    <citation>Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients. Diabetologia. 2002 Aug;45(8):1111-9. Epub 2002 Jul 4.</citation>
    <PMID>12189441</PMID>
  </reference>
  <reference>
    <citation>Meier JJ, Nauck MA, Pott A, Heinze K, Goetze O, Bulut K, Schmidt WE, Gallwitz B, Holst JJ. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology. 2006 Jan;130(1):44-54.</citation>
    <PMID>16401467</PMID>
  </reference>
  <reference>
    <citation>Schmidt WE, Siegel EG, Creutzfeldt W. Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia. 1985 Sep;28(9):704-7.</citation>
    <PMID>3905480</PMID>
  </reference>
  <reference>
    <citation>Sørensen LB, Flint A, Raben A, Hartmann B, Holst JJ, Astrup A. No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int J Obes Relat Metab Disord. 2003 Apr;27(4):450-6.</citation>
    <PMID>12664078</PMID>
  </reference>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2008</study_first_submitted>
  <study_first_submitted_qc>July 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2008</study_first_posted>
  <last_update_submitted>November 27, 2013</last_update_submitted>
  <last_update_submitted_qc>November 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Herlev Hospital</investigator_affiliation>
    <investigator_full_name>Asger Lund</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Glucagon</keyword>
  <keyword>Insulin</keyword>
  <keyword>Incretin hormones</keyword>
  <keyword>Glucose-dependent insulinotropic polypeptide</keyword>
  <keyword>Glucagon-like peptide-1</keyword>
  <keyword>Glucagon-like peptide-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Gastric Inhibitory Polypeptide</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

